Altium Capital Management LP Purchases Shares of 155,000 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Altium Capital Management LP acquired a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 155,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,886,000. Altium Capital Management LP owned about 0.38% of Xenon Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the company. Shell Asset Management Co. lifted its position in shares of Xenon Pharmaceuticals by 5.8% during the 2nd quarter. Shell Asset Management Co. now owns 26,245 shares of the biopharmaceutical company’s stock valued at $489,000 after acquiring an additional 1,440 shares during the last quarter. Swiss National Bank lifted its position in shares of Xenon Pharmaceuticals by 2.4% during the 1st quarter. Swiss National Bank now owns 64,000 shares of the biopharmaceutical company’s stock valued at $1,146,000 after acquiring an additional 1,500 shares during the last quarter. Citigroup Inc. lifted its position in shares of Xenon Pharmaceuticals by 212.2% during the 2nd quarter. Citigroup Inc. now owns 3,000 shares of the biopharmaceutical company’s stock valued at $56,000 after acquiring an additional 2,039 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Xenon Pharmaceuticals by 12.5% during the 2nd quarter. Geode Capital Management LLC now owns 21,650 shares of the biopharmaceutical company’s stock valued at $403,000 after acquiring an additional 2,408 shares during the last quarter. Finally, Eaton Vance Management acquired a new stake in shares of Xenon Pharmaceuticals during the 1st quarter valued at $45,000. Institutional investors own 81.51% of the company’s stock.

Shares of XENE traded up $0.65 during mid-day trading on Thursday, reaching $32.63. The company’s stock had a trading volume of 26,684 shares, compared to its average volume of 747,656. The business has a fifty day moving average of $19.34 and a 200 day moving average of $18.66. The company has a market cap of $1.34 billion, a price-to-earnings ratio of -21.61 and a beta of 1.36. Xenon Pharmaceuticals Inc. has a 1 year low of $9.32 and a 1 year high of $33.72.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Wednesday, August 11th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.02). Xenon Pharmaceuticals had a negative return on equity of 27.60% and a negative net margin of 323.04%. The firm had revenue of $2.22 million for the quarter, compared to analysts’ expectations of $2.58 million. Sell-side analysts predict that Xenon Pharmaceuticals Inc. will post -1.71 EPS for the current year.

XENE has been the subject of a number of recent research reports. Guggenheim increased their price objective on Xenon Pharmaceuticals from $30.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, October 4th. TheStreet lowered Xenon Pharmaceuticals from a “c-” rating to a “d+” rating in a report on Wednesday, September 22nd. Finally, Needham & Company LLC increased their target price on Xenon Pharmaceuticals from $25.00 to $48.00 and gave the company a “buy” rating in a report on Monday, October 4th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, Xenon Pharmaceuticals has an average rating of “Buy” and a consensus price target of $40.33.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company’s products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J.

See Also: Initial Coin Offering (ICO)

Institutional Ownership by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.